5Vemeris MR, Kornacker M, Mailander V, et al. Resistance of ex vivo expanded CD3 + CD56 + T cells to Fas-mediated apoptosis. Cancer Immunol Immunother,2000,49 (6) :335-345.
6Brandau S, Bohle A. Activation of natural killer cells by Bacillus Calmette-Guerin. Eur Urol, 2001,39 ( 5 ): 518 -524.
7Akagi J,Takai E,Tamori Y, et al. CD3 + CD56 + CD8 + cells demonstrating a suppressor T cell-like function in the peripheral blood of colon cancer patients. Int J Oncol,2001,19 ( 3 ) :561-566.
8Finke S,Trojaneck B, Lefterova P, et al. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3 +CD56 + immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther, 1998,5 (1): 31-39.
9Flieger D, Kufer P, Beier I, et al. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3 + CD56 + natural-killer-like T lymphocytes to EpCAM-expressing tumor cells. Cancer Immunol Immunother,2000,49 ( 8 ): 441-448.
10Marten A,Ziske C, Schottker B, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother ,2001,24 ( 6 ): 502-510.
